Clinical trials: Penile Diseases
Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered…
- Conditions
- Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis, Advanced Cancers
- Trial name
- NCT02571036
- Testing
- DCC-2618
- Where
- 26 sites in United States, Canada and 4 more
- Volunteers
- 282 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Penile Cancer, Anal Cancer
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
To evaluate the safety and tolerability of the 9vHPV vaccine in Chinese healthy male aged 9 to 45 years.
- Conditions
- Penile Cancer, Anal Cancer, PIN-1, PIN-2
- Trial name
- NCT05518201
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Peyronie's Disease
A Study of AA4500 in Men With Peyronie's Disease
This study is a Phase 3, open-label study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Subjects will be screened for study eligibility within 21 days before the initial injection of study drug…
- Trial name
- NCT01243411
- Testing
- AA4500
- Where
- 39 sites in United States, Denmark and 7 more
- Volunteers
- 348 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Bladder Cancer, Squamous Cell Carcinoma of the Lung
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have…
- Conditions
- Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma
- Trial name
- NCT07217171
- Testing
- EVOLVE104
- Where
- 16 sites in United States
- Volunteers
- 160 people
- Sponsor
- EvolveImmune United, Inc
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Human Immunodeficiency Virus (HIV)
SPL7013 Gel - Male Tolerance Study
The purpose of this study is to determine if SPL7013 Gel (VivaGel™) is safe when applied topically once a day for seven consecutive days to the shaft and glans of the penis in healthy male volunteers.
- Trial name
- NCT00370357
- Testing
- 3% w/w SPL7013 Gel (VivaGel™)
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Starpharma Pty Ltd
Adult Solid Tumor
Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of SQZ-PBMC-HPV as monotherapy and in combination with atezolizumab or other immune…
- Trial name
- NCT04084951
- Testing
- SQZ-PBMC-HPV, Atezolizumab, Ipilimumab
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- SQZ Biotechnologies
Pain, Neuropathic, Epilepsy
Cancer in Patients With Gabapentin (GPRD)
High doses of gabapentin are associated with pancreatic acinar cell tumors in rats, but there has been no post marketing pancreatic carcinogenicity signal with gabapentin as reported by spontaneous reports in AERS or in the…
- Conditions
- Pain, Neuropathic, Epilepsy, Renal Pelvis Cancer, Pancreatic Cancer
- Trial name
- NCT01236053
- Testing
- Gabapentin prescriptions
- Volunteers
- 2,323,608 people
- Sponsor
- GlaxoSmithKline
Priapism
A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism
The goal of the study was to evaluate the efficacy and safety of crizanlizumab in sickle cell disease (SCD) patients with priapism.
- Trial name
- SPARTAN (NCT03938454)
- Testing
- Crizanlizumab
- Where
- 13 sites in United States
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Erectile Dysfunction (ED)
Evaluation of the Rigicon Infla10® Inflatable Penile Prosthesis (IPP) for Erectile Dysfunction
This study evaluates the long-term safety and effectiveness of the Rigicon Infla10® Inflatable Penile Prosthesis in patients with erectile dysfunction.
- Trial name
- UNITED (NCT07273773)
- Testing
- Rigicon Infla10® Inflatable Penile Prosthesis (IPP)
- Where
- 4 sites in United States
- Volunteers
- 182 people
- Sponsor
- Rigicon, Inc.
Peyronie's Disease
Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease
This study is a Phase 2, open-label study to assess the pharmacokinetics (PK) and safety of AA4500 0.58 mg in men with Peyronie's disease.
- Trial name
- NCT01430169
- Testing
- AA4500
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Peyronie's Disease
A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease
This study is a Phase 3, open-label study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Subjects will be screened for study eligibility within 21 days before the initial injection of study drug…
- Trial name
- NCT01685437
- Testing
- AA4500
- Volunteers
- 189 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.
- Trial name
- NCT00082823
- Testing
- ziv-aflibercept
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
HPV-induced Cancers
Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers
The study will include 10 patients with HPV-associated ano-genital cancer (cervical, vulvar, vaginal, penile, anal) or HPV-associated head and neck cancer, who are planned to receive a cisplatin-based chemotherapy (alternatively…
- Trial name
- VICORYX-2 (NCT02526316)
- Testing
- P16_37-63 peptide combined with Montanide® ISA-51 VG, P16_37-63 peptide without Montanide® ISA-51 VG
- Where
- Germany
- Volunteers
- 11 people
- Sponsor
- Oryx GmbH & Co. KG
Cervical Cancer, Head and Neck Squamous Cell Carcinoma
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
A multicenter, open label, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 injection for HPV18 positive solid tumor.
- Conditions
- Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Carcinoma of Vagina, Carcinoma of Penis
- Trial name
- NCT05952947
- Testing
- HRYZ-T101 Injection, Fludarabine + Cyclophosphamide
- Where
- China
- Volunteers
- 32 people
- Sponsor
- HRYZ Biotech Co.
Erectile Dysfunction
Titan® One Touch Release Inflatable Penile Prosthesis
The purpose of this study is to assess the ease of deflation of the Titan® OTR pump.
- Trial name
- NCT00731939
- Testing
- Inflatable Penile Prosthesis
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 124 people
- Sponsor
- Coloplast A/S
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Adult Solid Tumor
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of SQZ-AAC-HPV as monotherapy and in combination with immune checkpoint inhibitors in…
- Trial name
- NCT04892043
- Testing
- SQZ-AAC-HPV, Ipilimumab, Nivolumab
- Where
- 6 sites in United States
- Volunteers
- 5 people
- Sponsor
- SQZ Biotechnologies
Peyronie's Disease
Additional Xiaflex® Treatment in Patients With Peyronie's Disease Recurrence, Worsening, or Incomplete Response
Subjects who have had an incomplete response to previous Xiaflex® will receive up to 4 additional cycles of treatment.
- Trial name
- NCT03767452
- Testing
- Xiaflex® 0.58 mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Manhattan Medical Research Practice, PLLC
Erectile Dysfunction
Rigicon Infla10® Three-Piece Inflatable Penile Prosthesis (ERASE ED)
This study evaluates the long-term safety and efficacy of the use of the Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis in patients with erectile dysfunction.
- Trial name
- ERASE-ED (NCT05574868)
- Testing
- Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis
- Where
- 7 sites in Australia
- Volunteers
- 182 people
- Sponsor
- Rigicon, Inc.